Emmessar Biotech Nutrition Ltd vs Occl Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: Mar 18, 2026

Key Highlights

The Latest Trading Price of Emmessar Biotech & Nutrition Ltd is ₹ 25 as of 18 Mar 15:30 . The P/E Ratio of Emmessar Biotech & Nutrition Ltd changed from 5.1 on March 2021 to 48.2 on March 2025 . This represents a CAGR of 56.71% over 5 yearsThe P/E Ratio of OCCL Ltd changed from 18.5 on March 2025 to 18.5 on March 2025 . This represents a CAGR of 0.00% over 1 years The Market Cap of Emmessar Biotech & Nutrition Ltd changed from ₹ 7.35 crore on March 2021 to ₹ 15.2 crore on March 2025 . This represents a CAGR of 15.64% over 5 yearsThe Market Cap of OCCL Ltd changed from ₹ 397.31 crore on March 2025 to ₹ 397.31 crore on March 2025 . This represents a CAGR of 0.00% over 1 years The revenue of Emmessar Biotech & Nutrition Ltd for the Dec '25 is ₹ 0.58 crore as compare to the Sep '25 revenue of ₹ 0.63 crore. This represent the decline of -7.94% The revenue of OCCL Ltd for the Dec '25 is ₹ 114.62 crore as compare to the Sep '25 revenue of ₹ 120.62 crore. This represent the decline of -4.97% The ebitda of Emmessar Biotech & Nutrition Ltd for the Dec '25 is ₹ 0.15 crore as compare to the Sep '25 ebitda of ₹ 0.17 crore. This represent the decline of -11.76% The ebitda of OCCL Ltd for the Dec '25 is ₹ 17.06 crore as compare to the Sep '25 ebitda of ₹ 20.21 crore. This represent the decline of -15.59% The net profit of Emmessar Biotech & Nutrition Ltd changed from ₹ 0.09 crore to ₹ 0.12 crore over 7 quarters. This represents a CAGR of 17.87% The net profit of OCCL Ltd changed from ₹ -0.04 crore to ₹ 6.53 crore over 7 quarters. This represents a CAGR of NaN% The Dividend Payout of Emmessar Biotech & Nutrition Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Dividend Payout of OCCL Ltd changed from 34.98 % on March 2025 to 34.98 % on March 2025 . This represents a CAGR of 0.00% over 1 years .

About Emmessar Biotech & Nutrition Ltd

Emmessar Biotech & Nutrition Limited (EBNL), originally established on 17th March 1992 as Emmessar Chemical Industries Ltd (ECIL) started its operations in manufacturing Super Specialty Fine Chemicals.
The Company has so far, succeeded in developing many Specialty Fine Chemicals.
ECIL gained official recognition for its R&D from DSIR, Ministry of Science & Technology, Government of India, New-Delhi in early 1996.
To better represent its new core activity, a change in the Company name from Emmessar Chemical Industries Ltd (ECIL) to Emmessar Biotech & Nutrition Ltd (EBNL) on April 7, 2000, was made essential. On realizing that some of the specialty chemicals developed & exported to USA & Europe was being used in producing healthcare formulations, the Company plunged into a new venture in the Healthcare business, where phenomenal growth in the coming decades was anticipated.

About OCCL Ltd

OCCL Limited was incorporated on April 25, 2022, at Mundra, Kachchh, Gujarat with a Certificate of Incorporation issued by the RoC. The Company belongs to the AG Ventures Group of companies.
The Company's first insoluble sulphur manufacturing facility, (transferred from demerged entity), was set up in 1994 in Dharuhera to manufacture insoluble sulphur, now its flagship product. The Company manufactures commercial grade and battery grade sulphuric acid and oleum at its Dharuhera Plant.
The Company's state-of-the-art manufacturing facilities are located in Dharuhera in Haryana and Mundra in Gujarat. The Company commenced production of Sulphuric Acid in 1978; commenced production capacity of 3,000 MT per annum Insoluble Sulphur in 1994; established a second line of business at Dharuhera in 2005; commenced construction of plant at Mundra in 2009; commissioned the first line of 5500 MTPA at Mundra Plant in 2011; commissioned the second line of insoluble sulphur at Mundra with production capacity of 5500 MTPA in 2012; expanded the additional 11,000 TPA of insoluble sulphur capacity at Mundra in 2016; commissioned the third line of insoluble sulphur with installed capacity of 5500 MTPA at Mundra Plant in 2017; commissioned the fourth line of insoluble sulphur with 5500 MTPA at Mundra in 2018; commissioned the expansion of 5500 MTPA insoluble sulphur at Dharuhera Plant in 2021; commissioned an additional 42000 MTPA capacity of sulphuric acid at Dharuhera Plant in 2022.

FAQs for the comparison of Emmessar Biotech & Nutrition Ltd and OCCL Ltd

Which company has a larger market capitalization, Emmessar Biotech & Nutrition Ltd or OCCL Ltd?

Market cap of Emmessar Biotech & Nutrition Ltd is 12 Cr while Market cap of OCCL Ltd is 440 Cr

What are the key factors driving the stock performance of Emmessar Biotech & Nutrition Ltd and OCCL Ltd?

The stock performance of Emmessar Biotech & Nutrition Ltd and OCCL Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Emmessar Biotech & Nutrition Ltd and OCCL Ltd?

As of March 18, 2026, the Emmessar Biotech & Nutrition Ltd stock price is INR ₹25.0. On the other hand, OCCL Ltd stock price is INR ₹88.09.

How do dividend payouts of Emmessar Biotech & Nutrition Ltd and OCCL Ltd compare?

To compare the dividend payouts of Emmessar Biotech & Nutrition Ltd and OCCL Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.